Sagimet Biosciences SGMT 深 滬

Sagimet to Share Mid-Stage Liver Disease Drug Data at Medical Conference

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an

04-06 19:09

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04-06 11:00

Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

Damora Therapeutics appoints Jennifer Jarrett as President and CEO effective March 30, 2026. Jarrett, with nearly three decades of experience in biotech, tech, and finance, will also join the Board. Biotech leaders Cameron Turtle and Mike Landsittel are added to the Board, while Peter Harwin becomes Chairman. Damora aims to redefine care for blood disorder patients with innovative therapies targeting mutant calreticulin-driven MPNs. The new leade...

03-23 12:00

美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级

今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元

03-12 12:34

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.

03-12 01:29

Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.48) by 39.08 percent. This is a 42 percent increase over losses of $(0.50) per share from

03-11 19:36

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Sagimet Biosciences announced its management will participate in three investor conferences in March 2026: the TD Cowen Health Care Conference in Boston, the Leerink Global Healthcare Conference in Miami, and the Citizens Life Sciences Conference in Miami. Fireside chats from the first two events will be available on Sagimet's website for 90 days. Sagimet is a biopharmaceutical company developing FASN inhibitors targeting metabolic and fibrotic p...

02-25 12:00

美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级

今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元

02-04 12:15

BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks

BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks Feb 2 (Reuters) - Sagimet Biosciences Inc SGMT.O : SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS’ OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) T

02-02 20:24

美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价

今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元

01-29 11:06